共 61 条
[1]
Mead GM(1997)International germ cell consensus classification: a prognostic factor- based staging system for metastatic germ cell cancers J Clin Oncol 15 594-603
[2]
Albers P(2015)Guidelines on testicular cancer: 2015 update Eur Urol 68 1054-1068
[3]
Albrecht W(1998)Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study J Clin Oncol 16 1287-1293
[4]
Algaba F(1997)Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial J Clin Oncol 15 1844-1852
[5]
Nichols CR(2018)Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors Ann Oncol 29 341-346
[6]
Catalano PJ(2011)Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish–Norwegian Testicular Cancer Group J Clin Oncol 29 2032-2039
[7]
Crawford ED(2017)Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013 Cancer Epidemiol Biomark Prev 26 632-641
[8]
Vogelzang NJ(2016)The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship Am J Surg Pathol 40 e94-e102
[9]
Einhorn LH(2012)Overview of the surveillance, epidemiology, and end results database: evolution, data variables, and quality assurance Curr Probl Cancer 36 183-190
[10]
Loehrer PJ(2014)Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis Eur J Surg Oncol 40 103-112